238 related articles for article (PubMed ID: 35917118)
21. Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.
Bertani L; Antonioli L; Fornili M; D'Antongiovanni V; Ceccarelli L; Carmisciano L; Benvenuti L; Mumolo MG; Bottari A; Pardi V; Baiano Svizzero G; Baglietto L; De Bortoli N; Bellini M; Fornai M; Costa F
Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38864707
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
24. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
[TBL] [Abstract][Full Text] [Related]
25. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
Hanžel J; Zdovc J; Kurent T; Sever N; Javornik K; Tuta K; Koželj M; Smrekar N; Novak G; Štabuc B; Dreesen E; Thomas D; Vovk T; Grabnar I; Drobne D
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):111-118.e10. PubMed ID: 32109630
[TBL] [Abstract][Full Text] [Related]
26. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
27. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.
Thomann AK; Schulte LA; Globig AM; Hoffmann P; Klag T; Itzel T; Teufel A; Schreiner R; Scheffe N; Ebert MP; Wehkamp J; Gauss A; Hasselblatt P; Klaus J; Reindl W
Z Gastroenterol; 2020 May; 58(5):439-444. PubMed ID: 32045954
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
30. Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study.
Miyazaki T; Watanabe K; Kojima K; Koshiba R; Fujimoto K; Sato T; Kawai M; Kamikozuru K; Yokoyama Y; Hida N; Nakamura S
Digestion; 2020; 101(1):53-59. PubMed ID: 31722356
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
[TBL] [Abstract][Full Text] [Related]
33. Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index.
Walshe M; Borowski K; Battat R; Hudesman D; Wolf DC; Okada L; Jain A; Silverberg MS
Crohns Colitis 360; 2021 Jul; 3(3):otab032. PubMed ID: 36776648
[TBL] [Abstract][Full Text] [Related]
34. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
Park J; Chun J; Yoon H; Cheon JH
Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
37. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS; Grova M; Mocciaro F; Di Mitri R; Privitera AC; Distefano ME; Vitello A; Camilleri S; Ferracane C; Pluchino D; Belluardo N; Giangreco E; Fries W; Viola A; Cappello M; D'Amato L; Bertolami C; Ventimiglia M; Renna S; Casà A; D'Antonio E; De Vivo S; Orlando A;
J Gastroenterol Hepatol; 2023 Sep; 38(9):1503-1509. PubMed ID: 37148148
[TBL] [Abstract][Full Text] [Related]
39. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
Straatmijer T; Biemans VBC; Hoentjen F; de Boer NKH; Bodelier AGL; Dijkstra G; van Dop WA; Haans JJL; Jansen JM; Maljaars PWJ; van der Marel S; Oldenburg B; Ponsioen CY; Visschedijk MC; de Vries AC; West RL; van der Woude CJ; Pierik M; Duijvestein M; van der Meulen-de Jong AE
J Crohns Colitis; 2021 Nov; 15(11):1920-1930. PubMed ID: 33909062
[TBL] [Abstract][Full Text] [Related]
40. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]